Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Green Valley Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodium Oligomannate

            Therapeutic Area: Neurology Product Name: GV-971

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Details:

            Green Valley’s treatment, known as GV-971, relies on a type of sugar extracted from brown algae. The drug aims to treat imbalances in the microbiome of the gut, which researchers believe may cause inflammation in the brain and may lead to Alzheimer’s or Parkinson’s disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodium oligomannate

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            Details:

            Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.